Supplementary TableS1.Summary of the commercially available proliferation-based gene-signatures in breast cancer

Signature / OncotypeDX® / MammaPrint® / Prosigna® / EndoPredict® / Breast Cancer IndexSM / Genomic Grade IndexTM
Early relapse / √ / √ / √ / √ / √ / √
Level of evidence / Ib / Ib / Ib / Ib / Ib / Ib
Late relapse / √ / ? / √ / √ / √ / ?
Can be performed on FFPE / √ / √ / √ / √ / √ / √
Validated in randomized study / √
(NSABP-B20) (1)
(ATAC)(2, 3)
(SWOG S8814)(4) / X / √
(ATAC)(2)
(ABCSG8)(5) / √
(ABCSG6,ABCSG8)(6) / √
(ATAC)(2)
(Stockholm TAM)(7) / √
(BIG 1-98)
(8, 9)
Subject to prospective validation / √
(TAILORx)
(RxPONDER) / √
(MINDACT) / X / X / X / √
(ASTER 70)

Legend: √ = Yes; X = No; ? = Unknown

Abbreviation: FFPE,formalin-fixed, paraffin-embedded.

References

1.Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–34.

2.Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013;14:1067–76.

3.Dowsett M, Cuzick J, Wale C, Forbes J, Mallon E, Salter J, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829–34.

4.Ishibe N, Schully S, Freedman A, Ramsey SD. Use of Oncotype DX in women with node-positive breast cancer. PLoS Curr 2011;3:RRN1249.

5.Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. AnnOncol 2014;25:339–45.

6.Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 2013;109:2959–64.

7.Zhang Y, Schnabel C, Schroeder B, Jerevall P, Jankowitz R, Fornander T, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res 2013;19:4196–205.

8.Desmedt C, Giobbie-Hurder A, Neven P, Paridaens R, Christiaens M-R, Smeets A, et al. The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial. BMC Med Genomics 2009;2:40.

9.Sotiriou C, Ignatiadis M, Desmedt C, Azim JH, Veys I, Larsimont D, et al. Abstract S4-4: Independent validation of Genomic Grade in the BIG 1-98 study [abstract]. In: Proceedings of the Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium: 2012 Dec 4–8; San Antonio, TX. Philadelphia (PA): American Association for Cancer Research;Cancer Res 2012;72(24 Suppl):Abstract nr S4-4.